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Abstract: Background: Cannabidiol (CBD) is among the major secondary metabolites of Cannabis 
devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. It is a resorcinol-based compound 
with a broad spectrum of potential therapeutic properties, including neuroprotective effects in numer-
ous pathological conditions. CBD neuroprotection is due to its antioxidant and antiinflammatory ac-
tivities and the modulation of a large number of brain biological targets (receptors, channels) involved 
in the development and maintenance of neurodegenerative diseases.  
Objective: The aim of the present review was to describe the state of art about the pre-clinical research, 
the potential use and, when existing, the clinical evidence related to CBD in the neurological field.  
Method: Collection of all the pre-clinical and clinical findings carried out investigating the effects of 
CBD alone, not in combination with other substances, in the neurological arena with the exclusion of 
studies on neuropsychiatric disorders.  
Results: Laboratory and clinical studies on the potential role of CBD in Parkinson’s disease (PD), 
Alzheimer’s disease (AD), multiple sclerosis (MS), Huntington’s disease (HD), amyotrophic lateral 
sclerosis ALS), cerebral ischemia, were examined.  
Conclusion: Pre-clinical evidence largely shows that CBD can produce beneficial effects in AD, PD 
and MS patients, but its employment for these disorders needs further confirmation from well de-
signed clinical studies. CBD pre-clinical demonstration of antiepileptic activity is supported by recent 
clinical studies in human epileptic subjects resistant to standard antiepileptic drugs showing its poten-
tial use in children and young adults affected by refractory epilepsy. Evidence for use of CBD in PD is 
still not supported by sufficient data whereas only a few studies including a small number of patients 
are available.  
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1. INTRODUCTION 
 The plant genus Cannabis contains a complex mixture of 
unique secondary metabolites-phytochemicals (over 60 com-
pounds) so-called cannabinoids of two large chemical types: 
delta-9-tetra-hydrocannabinol (THC) and cannabidiol (CBD). 
Cannabinoids are mixed polyketides derived biosynthetically 
from malonyl-CoA, hexanoyl-CoA units prenylated with 
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geranyl phosphate [1]. THC is the main psychoactive can-
nabinoid type, whereas CBD is a major component of Can-
nabis but it possesses a highly distinct pharmacological pro-
file with respect to THC. CBD (C21H30O2) is a resorcinol-
based compound devoid of the THC psychoactive effects 
and, on the contrary, is believed able to attenuate the psy-
chotomimetic effects induced by high doses of THC [2, 3]. 
THC and CBD have the same chemical formula but atoms 
are differently displayed (Fig. 1). 
 CBD was isolated in 1940 from marijuana and hashish. 
Marijuana consists of the desiccated flowers and leaves and 
stems of the female Cannabis plant, containing 3% to 20% 
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of THC, while industrial hemp has lower concentrations of 
THC and higher concentrations of CBD, which decreases the 
psychoactive effects and hashish is a concentrated resin from 
cannabis flowers and leaves or rasped from the surface of the 
plants and rotated into balls from Cannabis sativa var. indica 
[4, 5]. Its structure was elucidated by Mechoulam in 1963 [6] 
while its absolute configuration was definitively established 
later, in 1967 [7]. 
 The mechanism of action of CBD is complex and not 
fully known since this molecule behaves as a ‘multifaceted-
target’ drug interacting with several non-endocannabinoid 
systems such as receptors, ion channels, enzymes and trans-
porters [8, 9]. CBD modulates the activity of many cellular 
effectors, including the receptors CB1 and CB2 [10, 11], 
GPR55 [12], 5HT1A [13, 14] µ- and δ-opioid [15], perox-
isome proliferator-activated receptor gamma (PPARγ) [16, 
17], the transient receptor potential subfamily V member 1 
(TRPV1) cation channels [18] and fatty acid amide hydro-
lase (FAAH) [19].  
 The effects of CBD on intracellular signalling are largely 
independent of CB1 receptors [20]. While THC acts as a 
partial agonist of the CB1 and CB2 cannabinoid receptors, 
CBD does not have significant intrinsic activity over these 
receptors [21]. On cannabinoid receptors, CBD shows to 
have high potency as an antagonist [22]. CBD antagonizes 
CB1/CB2 receptors agonists and inhibits the reuptake of 
anandamide, the main endogenous cannabinoid. It is also an 
agonist of the serotonin 5-HT1A, glycine [23] and of the 
vanilloid receptors TRPV1, TRPV2, TRPA1 [9, 24].  
 CBD regulates calcium flux in a bidirectional change 
through control over intracellular calcium stores and it also 
produces biphasic changes in intracellular calcium levels via 
antagonism of the mitochondrial voltage dependent anion 
channel 1 [25]. CBD also antagonizes GPR55, working as a 
counterpart to the canonical CB1R/CB2R signalling pathway 
[26] and is a competitive inhibitor of adenosine uptake by 
the equilibrative nucleoside transporter 1 of macrophages 
and microglial cells, the resident macrophage-like immune 
cells of the brain [27].  
 Pharmacokinetic studies have showed that CBD, in vitro, 
inhibits a number of human CYP450 isoforms being a sub-
strate for human cytochrome P (CYP) 450 2C19 and 3A4, a 
potential substrate for the isoenzymes CYP3A5, CYP2C9, 
and UDP-glucuronosyltransferase isoforms 1A9, 2B7, and 
2B17 [28]. CBD has a large volume of distribution (32 l/kg) 
and it can be found in many tissues and organs, including the 
eye and the central nervous system (CNS) [29]. 
 Even not being a psychoactive compound, CBD has anti-
inflammatory and antioxidant properties and consequently 
has been considered as a potential new pharmacological ap-
proach for neuroprotection [8]. CBD anti-inflammatory and 
antioxidant activities can act in a synergistic way since it has 
been suggested that the antioxidant action ascribed to CBD 
on the basis of pre-clinical studies in various in vivo models 
of human diseases probably exceeds antioxidant activity 
expected on the basis of its chemistry alone [3].  
 Overall, studies suggest that CBD could be a favourable 
strategy in the neurological arena for the treatment of epi-
lepsy [8], neurodegenerative diseases such as Alzheimer's 
disease (AD) [30], Huntington's disease (HD) [31] and Park-
inson's disease (PD) [32], neonatal brain ischemia [33]. 
Moreover, it is noteworthy that CBD is not psychoactive but 
it can readily cross the blood brain barrier and exerts its ef-
fects at CNS level [34]. 
 It has been suggested that a clinical endocannabinoid 
system deficiency underlies many human diseases producing 
psychiatric disturbances [35, 36] such as mood disorders [37] 
and also CBD has been recently studied for its potential 
therapeutic effects in neuropsychiatric disorders such as 
schizophrenia [38], depression [39] and anxiety [40].  
 The aim of the present review was to describe the state of 
art of the pre-clinical research, about the potential use and, 
when existing, of the clinical evidence related to CBD in the 
neurological field.  
 The potential role of CBD for the management of neuro-
psychiatric diseases have yielded promising positive results 
[41, 42], however, in this review we consider and discuss 
only more strictly neurological CBD data about epilepsy, 
neurodegenerative disorders and neuromuscular diseases. 
Furthermore, with the aim to focus on CBD properties and to 
define CBD potential role in the neurological field, in the 
present article we took in consideration all the pre-clinical 
and clinical findings in which CBD alone has been investi-
gated, with the exclusion of research carried out with canna-
bis or THC/CBD herbal preparations.  
2. METHOD 
 All existing pre-clinical and clinical findings carried out 
investigating the effects of CBD alone, not in combination 
with other substances, in the neurological arena with the ex-
clusion of studies on neuropsychiatric disorders have been 
collected.  
 
 
Fig. (1). Chemical structures of Δ 9-tetrahydrocannabinol (THC) and cannabidiol (CBD).  
 
Neurological Aspects of Medical Use of Cannabidiol CNS & Neurological Disorders - Drug Targets, 2017, Vol. 16, No. 5    3 
 A bibliographic research was carried out independently 
by two researchers in the major scientific databases and search 
engines of peer-reviewed literature on life sciences and bio-
medical topics (PubMed, Scopus, Embase, Web of Science, 
Google Scholar) starting from January 1970 to November 
2016. Analysis included all articles published on peer-
reviewed scientific journals describing clinical trials and 
applications of CBD in the neurological field excluding stud-
ies on neuropsychiatric issues. Articles were excluded if they 
did not meet the following inclusion criteria: CBD used alone, 
not in combination with other substances and also articles 
written only in English language. Consequently, all scientific 
articles investigating on cannabis preparations or products 
containing THC or other compounds have been excluded.  
3. RESULTS 
 Pre-clinical and clinical studies on role of CBD in epi-
lepsy, Parkinson’s Disease (PD), Alzheimer’s Disease (AD), 
multiple sclerosis (MS), Huntington’s disease, amyotrophic 
lateral sclerosis, cerebral ischemia, were collected and fur-
ther evaluated.  
3.1. CBD pre-clinical and clinical studies on epilepsy 
 About a third of patients with epilepsy show a treatment-
resistant form, associated with severe morbidity and in-
creased mortality. Cannabis has been used for centuries for 
the treatment of epileptic disorders [43], but only in the last 
decades it has been demonstrated that CBD has anti-seizure 
activity. This property, together with the lack of psychotro-
pic effects and a good tolerability profile suggests that CBD 
could have a potential therapeutic role in epilepsy [44]. THC 
effects on epilepsy are controversial due to the reporting of 
pro- and anti-convulsant effects [45].  
 Overall, pre-clinical data obtained through experiments 
carried out on experimental animal models show that pre-
treatment with CBD produces anticonvulsivant effects. It has 
been reported that pre-treatment with CBD in vivo in mice 
prevents tonic-seizures induced by GABA inhibitors such as 
picrotoxin, pentylentetrazole (PTZ), bicuculline, isoniazide 
and by transcorneal electroshock [46]. CBD is able to stop 
tonic but not clonic seizures in animal models in which sei-
zures are induced by PTZ and maximal electroshock (MES). 
Thus, suggesting the hypothesis that CBD could act mainly 
to decrease the spreading of seizures, influencing only par-
tially seizures onset [47, 48]. Due to pharmacokinetic (CBD 
inhibits several cytochrome P450 isoenzymes) and pharma-
codynamic interactions, CBD could have opposite effects 
when given together with standard antiepileptic drugs to 
animals subjected to MES, since it increases phenytoin ef-
fects and reduces those of clonazepam and ethosuximide [49, 
50, 51].  
 CBD effects have been investigated on seizures induced 
by PTZ and MES, experimental models causing generalized 
convulsion. In these experiments, CBD reduced seizures and 
mortality and both in vitro and in vivo evidence shows that 
antiepileptic activity is not dependent from CB1 receptor 
[52]. Other authors furtherly suggested that CBD antiepilep-
tic activity in PTZ model, but not anti-seizure effects in MES 
model, could be mediated by big potassium (BK) channels 
characterized by large conductance for potassium ions (K+) 
[53]. 
 In a chronic experimental model of epilepsy induced by 
PTZ (28 days administration), in rats treated with CBD, were 
observed both reduction of neuronal death in CA1 and CA3 
hippocampal brain areas and hippocampal astrocytic hyper-
plasia. These effects were associated with decrease of hippo-
campal expression of N-methyl-d-aspartic acid receptor 
subunit 1 [54].  
 Intraperitoneal CBD administration (1-100 mg/kg) before 
pilocarpine-induced temporal lobe epilepsy reduced tonic-
clonic seizures with any influence on mortality, while the 
same substance (≥ 10 mg/kg) reduced both these two pa-
rameters when seizures were induced by penicillin [55]. Pro-
tection against seizures induced by CBD has been also re-
lated to its antioxidant activity and increase in autophagy at 
hippocampal cells level in a study in which the pilocarpine-
induced epilepsy, a temporal lobe epilepsy model, has been 
used. Through this model, it has been shown that CBD could 
enhance the induction of autophagy pathway and antioxidant 
defence in the chronic phase of epilepsy, which could be 
considered as a protective mechanisms in a temporal lobe 
epilepsy [56].  
 More recently, it has been suggested that CBD could 
exert its anticonvulsant effects, at least in part, through its 
actions on voltage-gated sodium channels and resurgent cur-
rent (an atypical near threshold current predicted to increase 
neuronal excitability) which has been implicated in multiple 
disorders of excitability, may be a promising therapeutic 
target for the treatment of epilepsy syndromes. This hypothe-
sis has been supported by a study examining the effects of 
CBD on endogenous sodium currents from striatal neurons 
and reporting CBD inhibition of resurgent and persistent 
sodium current [57] Pre-clinical research investigating on 
CBD effects in epilepsy are summarized in Table 1.  
 The first human study describing antiepileptic effects of 
CBD was published in 1980. The study comprised two 
phases, in the first CBD was given in a double-blind setting 
3 mg/kg daily for 30 days to 8 health human volunteers and 
other 8 volunteers received placebo. In the second phase of 
the study, 15 patients affected by secondary generalized epi-
lepsy with temporal focus were divided according to a ran-
dom scheme in two groups and received, following a double-
blind schedule, daily 200-300 mg of CBD or placebo for four 
and a half months. Clinical and laboratory data, electroen-
cephalogram (EEG) and electrocardiogram (ECG) were col-
lected or performed at intervals of 15- or 30-days. During the 
period treatment the patients continued to take the standard 
antiepileptic drugs prescribed before the study, although 
these drugs were no longer controlling the symptoms. CBD 
was well tolerated and no serious side effects were reported. 
Results showed that four of seven patients treated with CBD 
were almost free of epileptic crises and three other patients 
showed partial improvement [58].  
 CBD has also received great consideration as a potential 
therapy for pediatric epileptic syndromes. Experience of 
children with infantile spasms (IS) and Lennox–Gastaut syn-
drome (LGS) who have been treated with cannabis prepara-
tions enriched with CBD were collected through an online
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Table 1. Summary of pre-clinical studies on cannabidiol (CBD) effects in the neurological arena. 
Neurological 
Disease 
Cannabidiol Effects Experimental 
Model 
Dose Mechanism of Action References 
Pre-treatment with CBD in vivo in mice 
prevents tonic-seizures induced by gamma-
aminobutyric acid (GABA) inhibitors 
Mouse CBD 100-300 
mg/kg 
The differential effects of CBD suggest that it 
inhibits seizure spread in the CNS by action on 
GABA) 
[46] 
CBD stops tonic but not clonic seizures in 
animal models in which seizures are induced 
by pentylenetetrazol (PTZ) and maximal 
electroshock (MES). 
Mouse CBD 200 mg kg  Not investigated. CBD could act mainly to 
decrease the spreading of seizures, influencing 
only partially seizures onset. 
[47] 
CBD exerts anticonvulsant effects with 
significant decreases in incidence of severe 
seizures and mortality 
Rat CBD 100 mg/kg These findings suggest that CBD acts, poten-
tially in a CB1 receptor-independent manner, to 
inhibit epileptiform activity. 
[52] 
CBD produces antiepileptic activity in PTZ 
model, but not anti-seizure effects in MES 
model. 
Mouse CBD 100 mg/kg CBD antiepileptic activity could be mediated 
by big potassium (BK channels). 
[53] 
Epilepsy 
CBD protects against seizures induced by 
pilocarpine, a temporal lobe epilepsy model. 
Rat CBD 100 ng CBD could enhance the induction of autophagy 
and antioxidant defense, considered as a pro-
tective mechanisms in temporal lobe epilepsy. 
[56] 
CBD prevents neuronal damage induced by 
6-hydroxydopamine unilateral injection into 
the nigra pars compacta.   
Rat	   CBD 3 mg/kg CBD prevention in rodents is probably due to 
its antioxidant activity, associated with a CB 
receptor-undependent mechanism modulating 
glial responses and inhibition of dopaminergic 
transmission impairment. 
[67] 
CBD may exert protection against cell death 
and neurite loss induced by the neurotoxin 1-
methyl-4-phenylpyridinium on pheochromo-
cytoma-12 (PC-12) cells. 
In vitro: PC-12 
cells, neurobla-
stomaSH-SY5Y 
cells. 
CBD 1, 5, 10, 25 
and 50 µM 
CBD neuroprotection may involve activation of 
tropomyosin receptor kinase A  receptors, the 
increase of the expression of axonal and synap-
togenic proteins and CBD nerve growth factor-
like effects. 
[68] 
Parkinson’s 
Disease (PD)	  
CBD administration would attenuate reserpi-
ne-induced motor and cognitive impairments 
in vivo, an experimental model for the study 
of tardive dyskinesia and PD. 
Rat CBD 0.5 and 5 
mg/kg 
CBD’s antioxidant and anti-inflammatory 
actions are possibly involved in its beneficial 
effects on the reserpine model. 
[71] 
CBD produces neuroprotection against β-
amyloid when added to cultured neuronal 
cells. 
In vitro: PC-12 
cells 
CBD 10-6 to 10-4 Reduction of oxidative stress and blockade of 
apoptosis. 
[77] 
Decrease in β-amyloid production and β-
amyloid induced neurodegeneration. 
Mouse CBD 2.5 or 10 
mg kg 
CBD inhibition of nitrite production and induc-
ible nitric oxide synthase protein expression 
mediated through the inhibition of phosphory-
lated form of p38 mitogen-activated protein 
(MAP) kinase and transcription factor nuclear 
factor-B activation. 
[78] 
Alzheimer’s 
Disease (AD) 
Long-term CBD treatment (starting from 2.5 
months of age with CBD 20 mg/kg daily for 
8 months) in male amyloid β protein precur-
sor  × presenilin 1 mice, a transgenic model 
of AD, prevented social recognition deficit. 
Mouse CBD 20 mg/kg Impact of CBD on neuroinflammation, chole-
sterol level, and dietary phytosterol retention. 
[79] 
CBD administration improves clinical 
symptoms and reduces CNS immune infiltra-
tion, microglial activation, and axonal dama-
ge in the MS mouse model of myelin oligo-
dendrocyte glycoprotein 35-55-induced 
experimental autoimmune encephalitis. 
Mouse CBD 5 mg/kg Suppression of microglial activity and T-cell 
proliferation by CBD appears to contribute to 
the beneficial effects. 
[82] Multiple 
sclerosis (MS) 
Protective effects of CBD against the dama-
ge to oligodendrocyte progenitor (OPC) 
cells.  
In vitro: OPC 
cells 
CBD 2.5 and 5 
mM  
Decrease of caspase 3 induction and reduction 
of the production of reactive oxygen species at 
endoplasmic reticulum level. 
[85] 
 
(Table 1) Contd…. 
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Neurological 
Disease 
Cannabidiol Effects Experimental 
Model 
Dose Mechanism of Action References 
 Protective effects of CBD in experimental 
Theiler's Murine Encephalomyelitis Virus-
induced demyelinating disease. CBD atte-
nuated microglia activation and decreased 
transmigration of blood leukocytes. Long-
lasting ameliorating motor deficits in the 
chronic phase of the disease. 
Mouse CBD 5 mg/kg Downregulation of the expression of vascular 
cell adhesion molecule-1, chemokines (CCL2 
and CCL5) and proinflammatory cytokine 
interleukin-1β. Adenosine A2A receptors 
participate in some of the antiinflammatory 
effects of CBD. 
[86]	  
Amyotrophic 
lateral sclero-
sis (ALS) 
CBD produced modification in genes, patho-
genesis, oxidative stress, mitochondrial 
dysfunction and excitotoxicity, associated 
with ALS. 
In vitro: human 
gingival-
derived mesen-
chymal stromal 
cells (hGMSCs) 
CBD 5 µM CBD treatment in (hGMSCs) may downregula-
te genes that induce excitotoxicity. 
[96] 
CBD reduced cell death after oxygen-
glucose deprivation in immature mouse 
brain, an effect accompanied by CBD-
induced modulation of glutamate release, 
cytokine production, and cyclo-oxigenase-2 
and inducible nitric oxide synthase expres-
sion. 
Mouse In vitro: 
oxygen-glucose 
deprivedslices 
CBD 100 µM  Both cannabinoid and adenosine A2A recptors 
are involved, thus supporting the hypothesis 
that CBD exerts antinflammatory protective 
effects.  
[100]	  
Neuroprotective effects (increase of viable 
neurons) of CBD in a hypoxic-ischemic 
brain injury experimental model in newborn 
pigs induced by interruption of carotid blood 
flow for 30 minutes and reduction to 10% of 
the fraction of inspired oxygen.  
Newborn pigs CBD 1 mg/kg  CBD neuroprotective effects were reversed by 
co-administration either of 5-hydroxytryptamine 
1A (5-HT1A) receptor antagonist WAY100635 
or CB2 receptor antagonist AM630, suggesting 
the involvement of CB2 and 5-HT1A receptors. 
[14] 
CBD improved spatial learning performance 
and decreased hippocampal neurodegenera-
tion in mice subjected to bilateral common 
carotid artery occlusion  
Mouse CBD 10 and 30 
mg/kg 
Protective effects of on neuronal death induced 
by ischemia may involve the inhibition of 
reactive astrogliosis.  
[101] 
Brain  
ischemia 
Intracerebral administration of CBD produ-
ced reduction in neurological deficit, area of 
infarction, brain edema and blood brain 
barrier permeability in the cerebral ischemia 
induced by middle cerebral artery occlusion. 
Rat CBD 100 and 
200 ng 
These positive effects were associated in CBD 
treated animals with up-regulation of 
Na+/Ca2+ exchangers 2 and 3. 
[102] 
 
survey of parents who gave cannabis enriched with CBD as 
therapy for their children affected by epilepsy. People par-
ticipating to the survey included 117 parents of children with 
highly refractory epilepsy (including 53 subjects with IS or 
LGS). Average duration of treatment and the average dosage 
of CBD exposure were 6.8 months and 4.3 mg/kg/day, re-
spectively. Parents’ perceived efficacy and tolerability were 
similar across the subgroups and 85% all parents described a 
reduction in seizure frequency, and 14% reported that their 
children were complete seizure freedom. For a high percent-
age of children, improvement in sleep, alertness, and mood 
was also reported. Side effects were not common during 
CBD treatment, with the exception of an increase in appetite 
(30%). Even though the points of weakness, due to methodo-
logical issues (participation bias and lack of blinded proce-
dure) this study confirms the potential role for CBD in the 
treatment of refractory childhood epilepsy [59]. 
 Add-on therapy with oral CBD to the standard antiepilep-
tic regimen showed beneficial effects reported on the case of 
a 10-month-age boy with malignant migrating partial sei-
zures. Positive effects were normal growth and significant 
seizures reduction with the addition of CBD to his standard 
antiepileptic therapy. Treatment started with CBD 25 mg/mL 
at 10 mg/kg/day divided twice daily. Dose was increased to 
goal of 25 mg/kg/day divided twice daily over 15 days with 
no observed side effects [60]. 
 Children with febrile infection-related epilepsy syndrome 
(FIRES), after an acute phase with super-refractory status 
epilepticus, presented progression to a chronic phase with 
persistent refractory epilepsy. Evolution of this disease is 
exitus or severe encephalopathy. A study described 7 chil-
dren who received CBD after no response to all other drugs. 
CBD was gradually given up to a maximum dose of 25 
mg/kg/day. After CBD administration, in most of the pa-
tients an improvement in frequency and duration of seizures 
has been observed [61].  
 A retrospective multicenter study described the effects of 
CBD-enriched cannabis (CBD and tetrahydrocannabinol at a 
ratio of 20:1 dissolved in olive oil) at a dose ranging from 1 to 
20 mg/ kg/day for at least three months (average six months) on 
74 adolescents and children (aging 1-18 years) with intracta-
ble epilepsy resistant to more than 7 antiepileptic drugs and/ 
or other approaches such as ketogenic diet and/or vagal nerve 
stimulator implantation. Seizure frequency was assessed by 
parental report during clinical visits. CBD treatment yielded 
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a significant positive effect with parental report of reduction 
in seizure frequency. Improvement in behavior and alertness, 
language, communication, motor skills and sleep, was also 
observed. Adverse reactions such as somnolence, fatigue, 
gastrointestinal disturbances and irritability leading to with-
drawal of cannabis use in 5 patients were reported [62].  
 In another large-scale prospective multicentre open-label 
trial, patients (aged 1-30 years) with severe, intractable, 
childhood-onset, treatment resistant epilepsy, were treated 
with oral CBD (a 99% purified oil-based form of CBD) at 
doses of 2-5 mg/kg per day, up to a maximum dose of 25 mg/kg 
or 50 mg/kg per day. Patients were treated with CBD as an 
add-on treatment to their existing antiepileptic drugs. Motor 
seizure frequency and adverse events were monitored for 12 
weeks. CBD produced an average reduction in monthly mo-
tor seizures of 36.5%, similarly to the results obtained with 
the other antiepileptic drugs used in refractory epilepsy. 
However, CBD showed a slight not statistically significant 
greater efficacy in the subgroup of patients affected by 
Dravet or Lennox–Gastaut Syndromes. Results of this study 
confirmed the good tolerability of CBD for short term use 
[63].  
 Epilepsy is the most common neurologic manifestation of 
tuberous sclerosis complex (TSC), an autosomal-dominant 
genetic disorder. About 85% of patients with TSC is affected 
by epilepsy and in 63% epilepsy is resistant to drugs. CBD 
efficacy and tolerability has been investigated as an adjunct 
to current antiepileptic drugs in 56 TSC patients with refrac-
tory seizures. Patients were treated with the initial dose of 5 
mg/kg/day increased by 5 mg/kg/day every week up to a 
maximum dose of 50 mg/kg/day. Median weekly seizure 
frequency was reduced after three months of treatment with 
CBD. The 50% responder rates during the study were 50%, 
50%, 38.9%, 50%, and 50% after 2, 3, 6, 9, and 12 months 
of therapy, respectively. The authors concluded that CBD 
may be an effective and well-tolerated treatment option for 
patients with refractory seizures affected by TSC [64]. Clini-
cal studies on CBD in epilepsy are summarized in Table 2.  
 CBD has been shown to produce positive effects in  
preclinical studies on epilepsy. Results of scientific articles 
considered in this review indicate that CBD has antiepileptic 
activity. Several experiments have demonstrated that this 
cannabis derived compound may reduce seizure frequency 
and on the basis of a safe good profile could be used in sub-
jects, particularly in children and young adults, affected by 
treatment-resistant epilepsy. CBD showed beneficial effects 
in particular in children affected by Dravet or Lennox–
Gastaut Syndromes. The mechanisms through which CBD 
exerts its antiepileptic effects could be the activity on volt-
age-gated sodium channels and large conductance potassium 
channels, antioxidant activity, induction of autophagy path-
way. 
3.2. CBD Pre-Clinical and Clinical Studies on Parkin-
son’s Disease and Alzheimer’s Disease  
 CBD is a non-psychoactive compound of Cannabis sa-
tiva with antiinflammatory and antioxidant properties. These 
activities give to CBD a potential role for neuroprotection 
[65] and a large body of scientific evidence indicates that 
inflammatory processes are important in the pathophysiology 
of neurodegenerative disorders such as Parkinson’s disease 
(PD), Alzheimer’s disease (AD), multiple sclerosis (MS) 
[66].  
 PD is a progressive neurodegenerative disorder clinically 
characterized by symptoms such as tremor, bradykinesia, 
rigidity and postural instability and rigidity. These symptoms 
are produced by brain dopaminergic denervation at the stria-
tum level and progressive death of dopaminergic neurons in 
the pars compacta of the substantia nigra. Pre-clinical re-
search demonstrated that cannabinoids prevent neuronal 
damage induced by 6-hydroxydopamine unilateral injection 
into the nigra pars compacta in rodents probably by its anti-
oxidant activity, possibly associated a CB receptor-independent 
mechanism having the capability to modulate glial responses, 
which are relevant to neural survival. It has been also ob-
served that CBD exerts neuroprotective effects by inhibition 
of dopaminergic transmission impairment by attenuating 
dopaminergic cell death in experimental hemiparkinsonism, 
induced by the intranigral administration of 6-hydroxydopamine 
[67].  
 It has been shown that CBD may exert protection against 
the cell death and the neurite loss induced by the neurotoxin 
1-methyl-4-phenylpyridinium (MPP+) on PC12 cells. CBD 
neuroprotection may involve the activation of trkA (a family 
of tyrosine kinases that regulates synaptic strength and the 
plasticity in the mammalian nervous system) receptors and 
the increase of the expression of axonal and synaptogenic 
proteins. It has been also suggested that nerve growth factor 
(NGF)-like effects can contribute to CBD neuroprotective 
activity against the toxicity induced by MPP+, a neurotoxin 
relevant to development of PD [68]. 
 These effects support the potential neuroprotective role 
of CBD according to the findings that dysfunction of trophic 
factors could be involved in the pathogenesis of neurodegen-
erative diseases [69] and on the light of the evidence that 
reduction of neurotrophic factors such as brain-derived neu-
rotrophic factor (BDNF) and NGF has been found in brain 
and liquor of PD subjects [70].  
 More recently, it has been shown that CBD administra-
tion would attenuate reserpine-induced motor and cognitive 
impairments in vivo in rats. Repeated administration of re-
serpine in rodents provokes motor impairments associated 
with cognitive deficits, for this reason it is used as an ex-
perimental model for the study of tardive dyskinesia and PD. 
In vivo experiments showed that CBD (0.5 and 5 mg/kg) 
attenuates the increase in catalepsy behavior and in oral 
movements, and improved the reserpine-induced memory 
deficit in the discriminative avoidance task, but not the re-
duction in locomotion induced by reserpine [71]. Main  
pre-clinical data on CBD in PD are summarized in Table 1.  
 A first preliminary clinical open pilot study in humans, 
reported that CBD treatment (100–600 mg/day) for six 
weeks in five PD patients with dystonic movement disor-
ders, improved dystonia in all patients in a range from 20 to 
50%. Mild side-effects were reported including hypotension, 
dry mouth, psychomotor slowing, lightheadedness and seda-
tion [72]. 
 Successively, it has been observed that CBD at the dose 
of 160 mg/day could significantly improve the quality of sleep,
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Table 2. Summary of clinical studies carried out with cannabidiol (CBD) in the neurological arena. 
Disease Patients’ Pathologi-cal Characteristics  Study Design Population  Treatment Outcome  References 
Secondary general-
ized epilepsy with 
temporal focus. 
Randomized, 
controlled, 
double- 
blinded study. 
N = 15 patients, aging 14-49 
years, mean age 24. Two 
groups treated with CBD  
(N = 7) or placebo (N = 8). 
Two-three capsules/day 
containing CBD 100 mg 
for 4 and half months.  
Patients continued to take 
the antiepileptic drugs 
prescribed before the 
experiment, although 
they no longer controlled 
the disease. 
4 of the 8 subjects treated with CBD 
remained almost free of crises 
throughout the experiment and 3 other 
CBD patients demonstrated partial 
improvement. CBD was ineffective in 
1 patient. All patients and volunteers 
tolerated CBD very well and no signs 
of toxicity or serious side effects were 
detected. 
[58] 
Based on anecdotal 
reports reported by 
parents of children 
affected by highly 
refractory epilepsy.  
Open-label 
trial. 
Survey respondents included 
117 parents of children with 
epilepsy, including 53 with 
infantile spasms or Lennox-
Gastaut syndrome (LGS) who 
had administered CBD prod-
ucts to their children. Age 
range of children was 5 
months-10 years. 
The median duration and 
the median dosage of 
CBD exposure were 6.8 
months and 4.3 mg/kg/ 
day, respectively. 
Eighty-five percent of all parents 
reported a reduction in seizure fre-
quency and 14% reported complete 
seizure freedom. Most common re-
ported side effect was increased appe-
tite (30%).  
[59] 
Febrile infection-
related epilepsy 
syndrome (FIRES). 
Multicenter 
open study. 
7 children from 5 centers with 
FIRES who had not re-
sponded to antiepileptic drugs 
or other therapies. Age range 
from 3 years and 11 months 
to 8 years and 6 months. 
CBD was initiated and 
slowly titrated up to a 
maximum dose of 25 
mg/kg/day. 
Treatment with cannabidiol resulted in 
a marked reduction in seizure burden 
as defined as a decrease in seizure 
frequency and/or duration in 6/7 
subjects.  
[61]  
Pediatric refractory 
epilepsy. 
Retrospective 
study based 
on clinical 
records and 
phone call 
visits. 
74 patients aging 1-18 years 
with refractory epilepsy 
characterized by refractory 
daily seizures and >7 appro-
priate antiepileptic drugs and 
other treatments. 
CBD-enriched cannabis 
oil for more than 3 
months. CBD dosage 
ranged from 1 to 20 mg/ 
kg/d, and it was divided 
into two groups, 1-10 mg/ 
kg/d and 10-20 mg/kg/d.  
Most of the children (66/74; 89%) 
reported reduction in seizure fre-
quency. Improvement in behavior and 
alertness, language, communication, 
motor skills and sleep were observed. 
Adverse reactions included somno-
lence, fatigue, gastrointestinal distur-
bances and irritability. 
[62]  
Severe, intractable, 
childhood-onset, 
treatment resistant 
epilepsy. 
Multicenter 
open-label 
study. 
137 patients aging 1-30 years, 
with intractable childhood 
onset epilepsy, having four or 
more countable seizures with 
a motor component per 4 
week period, and receiving 
stable doses of antiepileptic 
drugs. 33 patients had Dravet 
syndrome and 31 patients had 
LGS. The remaining patients 
had intractable epilepsies of 
different causes and typology. 
Twelve weeks treatment 
of CBD 2-5 mg/kg per 
day divided in twice-
daily dosing added to the 
baseline antiepileptic 
drug regimen, then up-
titrated by 2-5 mg/kg 
once a week until intoler-
ance or a maximum dose 
of 25 mg/kg per day was 
reached. 
CBD reduced seizure frequency in 
children and young adults with highly 
treatment-resistant epilepsy. 
Adverse events reported were somno-
lence, decreased appetite, diarrhoea, 
fatigue, and convulsion.  
Serious adverse events were reported 
in 48 (30%) patients, including one 
death. 
[63]  
Epilepsy 
Patients with refrac-
tory seizures in the 
setting of tuberous 
sclerosis complex 
(TSC). 
Expanded-
access 
(compas-
sionate) 
study. 
Of the 56 patients who con-
sented and enrolled in current 
Institutional Review Boards 
and Food & Drug Admini-
stration approved expanded-
access study of CBD under 
Investigational New Drug 
119876, 18 patients have 
TSC.  
Eighteen of the 56 enrolled 
patients carried a diagnosis of 
TSC.  
Age range of 18 TSC patients 
was 2-31 years, mean age 
was 14 years.  
CBD initial dose of 5 
mg/kg/day divided in two 
doses was increased by 5 
mg/kg/day every week up 
to a maximum dose of 50 
mg/kg/day for 12 months 
added to standard ther-
apy. 
CBD reduced the median weekly 
seizure frequency. The most common 
adverse events were drowsiness, 
ataxia, and diarrhea. 
[64]  
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Disease Patients’ Pathologi-cal Characteristics  Study Design Population  Treatment Outcome  References 
Dystonic movement 
disorders (DMD) and 
PD. 
Open label 
study. 
Five patients with DMD. 
Patients No. 1, 3 and 5 were 
taking antidystonic medica-
tion but were only partially 
controlled by these drugs. 
Patient No. 4 had persistent 
disabling generalized dysto-
nia despite his current anti-
parkinsonism medication. 
Range age 31-65 years. 
CBD was started at 100 
mg/day and subsequently 
increased weekly by 100 
mg/day to a maximum of 
600 mg/day. 
CBD produced dose dependent  
improvement in dystonia in all pa-
tients, ranging from 20 to 50%. CBD 
side effects were mild and included 
hypotension, dry mouth, psychomotor 
slowing, lightheadedness, and seda-
tion.  
In 2 patients with coexisting Parkin-
sonian features, CBD at doses over 
300 mg/day exacerbated the hypokine-
sia and resting tremor. 
[72]  
Rapid eyes move-
ment sleep bevahiour 
disorder (RBD). 
Case series. Four patients affected by 
RBD with age range 59-71 
years. 
Three patients received 
CBD 75 mg/day, and one 
received CBD 300 
mg/day for 6 weeks. 
CBD produced prompt and substantial 
reduction in the frequency of RBD-
related events without side effects. 
[32]  
Parkin-
son’s 
Disease 
(PD) 
PD Randomized, 
controlled 
double 
blinded study. 
21 patients with diagnosis of 
idiopathic PD and use of 
stable doses of anti-Parkinson 
medications. Range age 51-
82 years; mean age 65.86 
years. 
CBD (75 mg/day or 300 
mg/day) for 6 weeks, 
No statistical difference between CBD 
and placebo in scores obtained with 
Unified Parkinson's Disease Rating 
Scale, used to assess PD symptoms, 
Parkinson’s Disease Questionnaire - 
39 to assess functioning and well-
being; and Udvalg for kliniske un-
dersøgelser side effect rating scale to 
evaluate possible adverse effects.  
[74]  
 
with reported increased total sleep time and lesser sleep 
fragmentation. Three doses of CBD (40, 80 and 160 mg/day) 
were shown to decrease dream recall without any adverse 
effects [73]. On the light of these findings, the effects of 
CBD at the average dose of 75 mg/day on rapid eyes move-
ments (REM) sleep behaviour disorder (RBD), characterized 
by a parasomnia with loss of muscle atonia during the REM 
phase of sleep accompanied with nightmares and active mo-
tor behaviour during dreaming, have been described in four 
patients with Parkinson’s disease. All the four patients 
treated with CBD had immediate and considerable reduction 
in the frequency of RBD-related events without any side 
effects [32]. 
 In another study, 21 PD patients without dementia or 
comorbid psychiatric conditions were divided in three groups 
of seven subjects each, who were treated with placebo, CBD 
75 mg/day or CBD 300 mg/day. No statistically significant 
differences in Unified Parkinson's Disease Rating Scale 
(UPDRS) scores, plasma BDNF levels or H(1)-magnetic 
resonance spectroscopy (MRS) measures of the three groups 
were found. However, the group treated with placebo and 
CBD 300 mg/day displayed significantly different mean total 
scores in the Parkinson's Disease Questionnaire (PDQ-39) (p 
= 0.05). According to the authors, results of the study indi-
cate a potential effect of CBD in improving quality of life in 
PD patients with no psychiatric comorbidities [74]. 
 CBD anti-inflammatory and antioxidant activities could 
be used in the treatment of PD. This role is supported by  
pre-clinical findings and preliminary clinical evidence. Neu-
roprotection in PD is not associated to a CB receptor mecha-
nism. Rather it is due to the modulation of glia activity re-
lated to the survival of neurons, inhibition of dopaminergic 
transmission, NGF-like effects, activation of trkA receptors. 
Clinical evidence of the CBD utilization at the range doses 
75-600 mg/day shows promising results but needs the per-
formance of larger scale studies. Main clinical findings about 
CBD in PD are summarized in Table 2. 
 AD is characterized by the presence of senile plaques 
formed by β-amyloid, neurofibrillary tangles, selective neu-
ronal loss, glial activation, associated with progressive cog-
nitive deficit. In the AD, brain damaged neurons and neurites 
and highly insoluble β-amyloid deposits and neurofibrillary 
tangles provide obvious stimuli for inflammation [75]. Brain 
β-amyloid formation due to the cleavage of amyloid precur-
sor protein is considered crucial for the development of this 
disease. Alteration in neuronal homeostasis together with 
and oxidative damage cause tangle formation and neuronal 
loss. CBD produces neuroprotection against the β-amyloid 
when added to cultured neuronal cells because it may benefi-
cially interfere with several β-amyloid-triggered neurode-
generative pathways. Several mechanisms have been sug-
gested to explain CBD neuroprotection, they are reduction of 
oxidative stress and blockade of apoptosis [76], capability to 
induce the ubiquitination of APP protein with consequent 
decrease in β-amyloid production [77], reduction of β-
amyloid-induced neuroinflammation and promotion of neu-
rogenesis through selective activation of peroxisome prolif-
erator-activated receptor-γ (PPARγ) [16], inhibition of in-
ducible nitric oxide synthase (iNOS) and interleukin-1β pro-
tein expression and release [78]. 
 In vitro and in vivo experiments showed that CBD could 
reverse cognitive deficits of AD transgenic mice through its 
anti-oxidant and anti-inflammatory properties. Long-term 
CBD treatment (starting from 2.5 months of age with CBD 
20 mg/kg daily for 8 months) in male AβPPSwe/PS1ΔE9 
(AβPP × PS1) mice, a transgenic model of AD, prevented 
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social recognition deficit that develops in this experimental 
model. Prevention of the social recognition deficit in mice 
was not accompanied with any changes in amyloid deposit or 
oxidative parameters. However, the study showed a slight 
impact of CBD on neuroinflammation, cholesterol level, and 
dietary phytosterol retention. The results of this study pro-
vide the evidence that CBD may have potential as a preven-
tion treatment for AD with a particular relevance in prevent-
ing symptoms of social withdrawal and facial recognition 
[79]. CBD treatment for a shorter time (20 mg/kg, daily in-
traperitoneal injections for 3 weeks), also reversed Aβ-
induced spatial memory deficits in the same transgenic ro-
dents [80]. Main pre-clinical findings of CBD in AD are 
summarized in Table 1. 
 Clinical evidence of use of CBD alone, not in combina-
tion with THC in AD, is not available. A review has been 
published a few years ago collecting clinical trials on the 
effects of THC:CBD combination products but the conclu-
sions showed no clear evidence that cannabinoids are effec-
tive in the improvement of disturbed behaviour in dementia 
and/or in the treatment of other symptoms of dementia [81]. 
 The source of data supporting the use of CBD in AD is 
still essentially consisting in pre-clinical experiments, while 
clinical studies with CBD in PD patients are only a few and 
including a small number of involved subjects. However, CBD 
has demonstrated significant promising effects in pre-clinical 
models of these disorders suggesting a more deep investiga-
tion to clarify the potential clinical utility of CBD. 
3.3. CBD Pre-clinical and Clinical Studies on Multiple 
Sclerosis  
 CBD has significant immunomodulatory activity and 
induces anti-inflammatory effects in several in vivo experi-
mental animal models of diseases involving T cells (cells 
playing a central role in cell-mediated immunity) such as 
collagen-induced arthritis, autoimmune diabetes, and auto-
immune hepatitis [82]. Multiple sclerosis (MS), is a neu-
rodegenerative autoimmune disease resulting in progressive 
paralysis mediated by T cells targeting myelin surrounding 
the the nerve fibers [83]. It has been shown that CBD ad-
ministration improves clinical symptoms and reduces CNS 
immune infiltration, microglial activation, and axonal dam-
age in the MS mouse model of myelin oligodendrocyte gly-
coprotein (MOG)35-55-induced experimental autoimmune 
encephalitis (EAE) [84]. Protective effects of CBD against 
the damage to oligodendrocyte progenitor cells are mediated 
by decrease of caspase 3 induction and reduction of the pro-
duction of reactive oxygen species at endoplasmic reticulum 
level [85]. 
 Protective effects of CBD in MS have been demonstrated 
also in experimental TMEV (Theiler's Murine Encephalo-
myelitis Virus)-induced demyelinating disease (IDD). 
Through the use of TMEV-IDD tool it has been found that 
CBD attenuates microglia activation and decreases the 
transmigration of blood leukocytes by the downregulation of 
the expression of vascular cell adhesion molecule-1 (VCAM-
1), chemokines (CCL2 and CCL5) and proinflammatory 
cytokine interleukin(IL)-1β. Moreover, CBD administration 
at the time of viral infection exerted also long-lasting amelio-
rating motor deficits in the chronic phase of the disease [86]. 
 The mechanism through which CBD produces protective 
effects in experimental MS is not completely known but it 
has been proved that CBD was able to decrease in mice the 
function of encephalitogenic Th17 cells as well as the pro-
duction and the release of IL-6 (controlling Th17 differentia-
tion) and IL-17 from encephalitogenic myelin oligodendro-
cyte glycoprotein MOG35-55-specific T cells [87, 88]. 
Moreover, CBD reduced STAT3 phosphorylation modulat-
ing Th17-like function of memory TMOG cells and in-
creased the production of anti-inflammatory cytokine IL-10 
[89].  
 Positive effects on the experimental autoimmune en-
cephalomyelitis (EAE) model characterized by reduction of 
inflammation, demyelination, axonal damage and inflamma-
tory cytokine expression, were obtained by treatment with 
CBD (5 mg/kg) injection for three consecutive days at the 
onset of appearance of disease signs [90].  
 Another study confirmed these findings by using a for-
mulation based on a cream containing 1 % of purified CBD 
(>98 %), as a daily topical treatment in EAE. The study re-
ported that treatment reduced symptomatic disease score 
(mean of 5.0 in EAE mice vs 1.5 in EAE + CBD-cream), 
recovered by paralysis of hind limbs and ameliorated his-
tological features typical of EAE (lymphocytic infiltration 
and demyelination) in spinal cord tissues [91]. The same 
group of researchers observed that CBD treatment is able to 
avoid apoptotic pathway activation through FAS pathway 
modulation and that CBD interferes with p53-p21 axis, rele-
vant for cell cycle regulation and the DNA damage response. 
These findings were associated with absence of tissue 
apobody formation in spinal cord tissues of EAE-mice 
treated with CBD [92]. Main pre-clinical findings on CBD in 
MS are summarized in Table 1. Despite the promising ex-
perimental evidence for a CBD positive role in the care of 
MS, the numerous clinical studies are exclusively centered 
on the effects of the combination THC:CBD. One of the 
main reasons is surely the ascertained spasmolytic and anal-
gesic effect warranted by THC.  
3.4. CBD Pre-Clinical and Clinical Studies on other Neu-
rodegenerative Diseases  
 Some beneficial effects of CBD in Huntington’s disease 
(HD), a genetic neurodegenerative disorder with symptoms 
that are considered as the expression of the progressive dys-
function and neuronal death in corticostriatal circuits, were 
shown in a non-blinded small study (four patients) [93]. HD 
is caused by a mutation in the gene encoding the protein 
huntingtin consisting of a CAG triplet repeat expansion 
translated into an abnormal polyglutamine tract in the amino-
terminal portion of huntingtin, which consequently is toxic 
for specific striatal and cortical neuronal subpopulations 
[94]. The effects of CBD at the dose of 10 mg/kg/day for 6 
weeks were investigated in 15 neuroleptic-free patients with 
HD in a randomized-controlled double-blinded cross-over 
study. Results of this study did not show any positive or 
toxic effects in comparison to placebo [95]. 
 The effects of CBD on genes associated with the progres-
sive neurodegenerative disease amyotrophic lateral sclerosis 
(ALS) have been studied by using human gingiva-derived 
mesenchymal stromal cells (hGMSCs) as an in vitro model 
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system. Results on hGMSCs treated with CBD showed 
modification in genes associated with pathogenesis, oxida-
tive stress, mitochondrial dysfunction and excitotoxicity in 
ALS. Authors’ conclusions suggest that CBD treated hGMSCs 
may serve as potential therapeutic approach for ALS patients 
[96]. 
3.5. CBD Pre-clinical and Clinical Evidence on Cerebral 
Ischemia 
 CBD can influence excitotoxicity following ischemic 
events. This is due to the fact that this secondary metabolite 
of cannabis plant has a dual role in the regulation of intracel-
lular calcium, whose excessive accumulation is a key process 
leading to neuronal death or injury. Excitotoxicity and 
changes of sodium and calcium homeostasis trigger patho-
physiologic processes in brain ischemia which can facilitate 
death of neurons. Normally, in physiological conditions, 
CBD increases intracellular calcium from intracellular cal-
cium stores and voltage-gated calcium channels, while under 
high-excitability conditions it maintains calcium homeostasis 
through mitochondrial Na+/Ca2+ exchanger (NCX) [25], a 
membrane antiporter that efflux calcium in exchange of so-
dium influx, that increasing its activity could facilitate neu-
ronal survival in brain ischemia [97].  
 Cannabinoids have been suggested as promising sub-
stances to be used for reduction of hypoxic-ischemic (HI) 
brain damage in newborns [98]. It has been reported that the 
CB1–CB2 agonist WIN552122 reduces brain damage after HI 
insults in in vitro and in vivo models in newborn rats, by 
modulating excitotoxicity, inflammation, and toxic nitric 
oxide (NO) production [99]. 
 Mechanisms involved in CBD-induced neuroprotection 
in HI immature brain have been investigated by using fore-
brain slices from newborn mice underwent oxygen and glu-
cose deprivation. CBD was investigated alone or with selec-
tive antagonists of cannabinoid CB1 and CB2, and adenosine 
A1 and A2 receptors. Experiments showed that CBD reduced 
acute HI brain damage by reducing glutamate and IL-6 con-
centration, and tumor necrosis factor (TNF) α, cyclooxy-
genase-2 and inducible nitric oxide synthase expression. 
CBD effects were reversed by the CB2 antagonist AM630 
and by the A2A antagonist SCH58261. The A1A antagonist 8-
cyclopentyl-1,3-dipropylxanthine (DPCPX) only inhibited 
the CBD reduction of glutamate release, while the CB1 an-
tagonist SR141716 did not modify any effect of CBD. Authors 
suggestions were that CBD induces neuroprotection in im-
mature brain, and these effects are mediated by CB2 and 
adenosine, mainly through A2A receptors [100]. 
 The mechanisms underlying the neuroprotective effects 
of CBD were investigated in vivo by using a hypoxic-ischemic 
(HI) brain injury experimental model in newborn pigs in-
duced by interruption of carotid blood flow for 30 minutes 
and reduction to 10% of the fraction of inspired oxygen. 
Treatment with CBD 1 mg/kg thirty minutes after HI, in-
creased the number of viable neurons and affected in a posi-
tive manner the amplitude-integrated EEG background activity 
as well as prognostic proton-magnetic-resonance-spectroscopy 
and HI brain damage parameters such as increased gluta-
mate/N-acetylaspartate ratio, oxidative stress and inflamma-
tion (increased brain IL-1 levels). CBD neuroprotective ef-
fects were reversed by co-administration either of serotonin 
5HT1A receptor antagonist WAY100635 or of the CB2 re-
ceptor antagonist AM630, suggesting the involvement of 
CB2 and 5HT1A receptors [14].  
 In another experiment, mice were subjected to a 17 min 
of bilateral common carotid artery occlusion (BCCAO) and 
successively subjected to the Morris water maze test 7 days 
later. CBD (3, 10, and 30 mg/kg), administered 30 min be-
fore and 3, 24, and 48 h after BCCAO, CBD (3-30 mg/kg) 
improved spatial learning performance and CBD (10 and 30 
mg/kg) showed a decrease in hippocampal neurodegenera-
tion after treatment. These results support the idea that pro-
tective effect of CBD on neuronal death induced by ischemia 
may involve the inhibition of reactive astrogliosis [101]. 
 Recently, other results from pre-clinical studies seem to 
provide further evidence for the potential antiischemic ef-
fects of CBD. It has been observed that, as it happens with 
hypothermia, CBD treatment reduced the glutamate/N-
acetyl-aspartate ratio, as well as TNF-α and oxidized protein 
levels in newborn piglets subjected to hypoxic-ischemic in-
sult [33]. Another very recent experiment of 2016, showed 
that intracerebral administration of CBD (100 and 200 ng/ 
rat) in the cerebral ischemia induced by middle cerebral ar-
tery occlusion, produced a remarkable reduction in neuro-
logical deficit, area of infarction, brain edema and blood 
brain barrier permeability with respect to the vehicle group. 
These positive effects were associated in CBD treated ani-
mals with up-regulation of NCX2 and NCX3 [102]. 
 Hypothermia is a standard treatment for neonatal en-
cephalopathy, but it is not giving always the expected posi-
tive results. The combined effect of hypothermia and CBD 
has been studied in hypoxic-ischemic newborn piglets. 
Combination of CBD with hypothermia, 30 minutes after the 
ischemic insult, has showed a higher effect in comparison to 
the protective effect of the two singular treatments on excito-
toxicity, inflammation and oxidative stress, and on cell dam-
age. Thus suggesting that CBD and hypothermia could act 
complementarily having additive effects on the main factors 
leading to hypoxic-ischemic brain damage if applied rapidly 
after the insult [33]. 
 By using the experimental model characterized by bilat-
eral common carotid artery occlusion (BCCAO) in mice, it 
has also been demonstrated that short-term CBD 10 mg/kg 
treatment attenuates cognitive and emotional impairments 
induced by brain ischemia. BCCAO mice showed long-
lasting functional deficits characterized by increase in anxi-
ety-like behavior, memory impairments, despair-like behav-
ior. CBD prevented the cognitive and emotional impair-
ments, attenuated hippocampal neurodegeneration and white 
matter injury, and reduced glial response that were induced 
by BCCAO, thus improving global functional recovery. In 
BCCAO ischemic mice treated with CBD an increase in the 
hippocampal BDNF protein levels, stimulation of neuro-
genesis and promotion of dendritic restructuring in the hip-
pocampus were also observed [103]. Main pre-clinical find-
ings on CBD in brain ischemia are summarized in Table 1. 
 Pre-clinical data indicated that CBD administration after 
a cerebral ischemic event produced long-lasting neuroprotec-
tive effects. In particular CBD was effective in recovering 
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post-ischemic functional parameters. Neuroprotection ob-
served with CBD is due to a large spectrum of effects such 
as maintenance of calcium homeostasis and reduction of 
inflammation mediators formation and indicated that CBD has 
potential as a new neuroprotective strategy in brain ischemia.  
CONCLUSION 
 CBD has been demonstrated to possess a broad spectrum 
of therapeutic properties, including neuroprotective effects in 
numerous pathological conditions. Neuroprotection could be 
explained with variegate biological properties observed with 
CBD. It exerts antioxidant and antiinflammatory activities 
and is able to modulate positively a large number of biologi-
cal targets in the brain involved in the development and 
maintenance of neurodegenerative diseases. Pre-clinical evi-
dence largely shows that CBD can produce beneficial effects 
in AD, PD and MS patients, but its employement for these 
disorders needs further confirmation through well designed 
clinical studies. Experimental animal studies also indicate 
that CBD could be useful as neuroprotective agent in the 
ischemic event occurring during the neonatal period. Pre-
clinical demonstration of antiepileptic activity is supported 
but recent studies in human epileptic subjects indicating 
CBD’s potential use in children and young adults affected by 
refractory epilepsy. Currently, therapeutic continuity by us-
ing cannabis or single cannabinoids is more guaranteed by 
standardized preparations assuring the availability of a ho-
mogeneous product of defined stability [104]. Consequently, 
clinical evidence reporting effectiveness of CBD is increased 
even if, in the neurological field, it is limited to epilepsy and 
PD. These findings indicate CBD as a promising potential 
treatment for refractory epilepsy in children and young 
adults, as suggested by several clinical studies that need to be 
confirmed by further clinical research. Evidence for use of 
CBD in PD is still not supported by sufficient data because 
only a few studies including a small number of patients are 
available.  
LIST OF ABBREVIATIONS  
AD  = Alzheimer's Disease 
ALS  = Amyotrophic Lateral Sclerosis 
BDNF  = Brain-derived Neurotrophic Factor 
CBD  = Cannabidiol 
CNS  = Central Nervous System 
EAE  = Experimental Autoimmune Encephalitis 
HD  = Huntington's Disease 
HI  = Hypoxic-ischemic 
5-HT1A = 5-Hydroxytryptamine 1A Receptor 
MES  = Maximal Electroshock 
MS  = Multiple Sclerosis 
NGF  = Nerve Growth Factor 
PD  = Parkinson's Disease 
PTZ  = Pentylentetrazole 
THC  = Delta-9-tetra-Hydrocannabinol 
TSC  = Tuberous Sclerosis Complex 
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